Next Phase Newsletter

A hybrid family office and operating company based can make investments ranging from $500k-100M into companies, and due to its funding structure, has no requirements for holding period or capital structure. The firm makes investments in the forms of equity, controlling interest, in-licensing, MBO/LBO, growth capital and is also willing to co-invest. The firm is looking for companies located around the globe and makes opportunistic and strategic investments, and does not have a target minimum or maximum number of investments for any given year. 
 
The firm is primarily looking for companies in the Therapeutics sector and is willing to consider all indications including orphan diseases, though they have some additional interest/experience is areas of ophthalmology, dermatology, diabetes, oncology, and Personalized Medicine including Proteomics and Genomics. The firm is most interested in companies that are clinical stage, but also capable of supporting companies nearing commercialization where the firm is capable of utilizing its operating company to scale up the company’s sales, marketing and distribution. That being said the firm has made earlier stage investments in the past and is open to considering highly innovative and compelling early stage companies. 
 
The firm looks to work with management teams with experience and grit and generally looks to take a board seat although it is not a requirement. The firm looks to leverage the use of its operating company to assist the company’s sales marketing and distribution efforts as well as providing assistance in operations management and product development.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm actively works to facilitate the creation, improvement, and validation of new medicines and health technologies. Its partnerships with portfolio companies and industry open up new horizons in precision medicine in realizing its mission to accelerate the innovation cycle through accessible solutions designed to improve patient’s health. Typically participating in Series A rounds, initial check size ranges between $1M-5M USD. The firm can act as a lead or co-investor and is open to global companies. 
 
The firm’s investments will transform healthcare through close collaborations with its metabolomics laboratory, merging AI and biomarker analysis to support the international growth of innovative companies. The firm is interested in life sciences facilitating drug discovery, and improving diagnosis, treatment, and monitoring of metabolomic conditions such as cancer, cardiovascular diseases, diabetes, antimicrobial, antibiotics resistance, and neurodegenerative diseases. 
 
The firm prefers to take a board or observer seat. Investments will be complemented with lab services to measure toxicity and response or therapies or accuracy of health technology. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A tech-driven pharmaceutical company based in the U.S. leverages its AI-powered drug development platform, the firm seeks to acquire promising drug candidates and develop them in-house faster and more efficiently than industry norms. The firm is interested in early clinical-stage therapeutic assets, and its typical deal structures include acquisitions and in-licensing. While equity investments are occasionally possible, the firm prefers to take a majority share and does not typically act as a minority investor. The firm is open to opportunities globally. 
 
The firm is interested in traditional therapeutic assets such as small molecules and biologics, with a primary focus on immunology, dermatology, and orphan diseases. Other indications of interest include CNS, cardiovascular, and metabolic diseases. The firm generally avoids cell therapy and oncology. As for development phases, the earliest the firm will consider is within 12 months of IND, with no limitation on how late the asset is in the clinical stage. 
 
The firm does not have specific requirements for a company’s management team, as the firm aims to take over the asset and typically does not act as a minority investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

An early-stage investment fund supporting innovation across human health, food, agriculture, and climate, brings experience and expertise across both investing & operating in the Food and BioTech, ClimateTech and AgTech sectors. Its operating model allows access into the nearly 100 years of capability, ingenuity, manufacturing and distribution experience within Fonterra, while maintaining the agility and responsiveness to be a strong partner to start-ups and innovators in the space. 

The firm typically invests in seed to Series A opportunities, though remains open to companies at later stages. The average check size ranges from $2M to $5M USD, with the ability to go beyond this. The fund is open to both leading and co-investing and will consider board positions on a case-by-case basis. The firm is actively seeking opportunities globally and is open to deal structures beyond equity investments, such as co-development and in-licensing, especially for technologies that align strategically with Fonterra. 
 
The firm is generally interested in technologies that use nutrients to improve human health, such as those targeting the microbiome, cognitive function, sleep, and more. Areas of interest include the microbiome, alternative ingredients, and the application of molecules and proteins. The fund places a strong emphasis on data. In terms of development stages, the firm is open to working with companies from the pre-clinical stage through all phases of clinical and commercial development. 
 
The firm does not have specific requirements for the company or management team. However, the fund seeks founding teams with passion and strong technical expertise. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.